Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $55.56 Consensus Price Target from Brokerages

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) have been assigned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $55.5556.

A number of brokerages have weighed in on TERN. Jefferies Financial Group reissued a “buy” rating and issued a $70.00 target price on shares of Terns Pharmaceuticals in a research report on Wednesday, December 10th. Truist Financial lifted their price target on shares of Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. JMP Securities set a $35.00 price objective on shares of Terns Pharmaceuticals in a research report on Wednesday, November 26th. Oppenheimer raised their target price on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Finally, William Blair upgraded shares of Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, November 3rd.

Terns Pharmaceuticals Trading Up 1.9%

Shares of TERN stock opened at $35.09 on Friday. The company’s fifty day moving average price is $36.37 and its 200-day moving average price is $18.52. The stock has a market cap of $3.16 billion, a PE ratio of -34.07 and a beta of -0.28. Terns Pharmaceuticals has a 12 month low of $1.87 and a 12 month high of $48.26.

Terns Pharmaceuticals (NASDAQ:TERN) last released its earnings results on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.03. On average, sell-side analysts forecast that Terns Pharmaceuticals will post -1.19 earnings per share for the current fiscal year.

Insider Transactions at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 1,155 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the sale, the insider owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. The trade was a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Amy L. Burroughs sold 68,749 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $37.07, for a total transaction of $2,548,525.43. Following the completion of the transaction, the chief executive officer directly owned 288,976 shares of the company’s stock, valued at $10,712,340.32. This represents a 19.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 165,763 shares of company stock worth $5,752,450 in the last three months. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in shares of Terns Pharmaceuticals by 762.4% during the fourth quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after buying an additional 770 shares during the period. Engineers Gate Manager LP bought a new stake in shares of Terns Pharmaceuticals during the 2nd quarter worth approximately $41,000. Canada Pension Plan Investment Board purchased a new position in Terns Pharmaceuticals during the 2nd quarter valued at $46,000. Dynamic Technology Lab Private Ltd bought a new position in Terns Pharmaceuticals in the 1st quarter valued at $51,000. Finally, Velan Capital Investment Management LP increased its stake in Terns Pharmaceuticals by 17.6% in the second quarter. Velan Capital Investment Management LP now owns 20,000 shares of the company’s stock worth $75,000 after purchasing an additional 3,000 shares during the period. 98.26% of the stock is currently owned by institutional investors.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.